Cure My Disease

Don't miss your cure!

 Log in / Sign up

Light and vitamin B2 eyedrops tested against corneal blood vessel growth

NCT ID NCT04787471

Disease control Sponsor: Price Vision Group Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Researchers compare two versions of corneal crosslinking to treat corneal neovascularization, a condition where abnormal blood vessels grow into the clear front surface of the eye. Both versions use riboflavin eye drops followed by ultraviolet A light, but one shines the light for 30 minutes at lower intensity and the other for 10 minutes at higher intensity. The trial enrolls adults with active inflammation or infection, vessel growth that threatens a corneal transplant, or vessels that keep growing despite steroid drops. Doctors photograph the cornea and measure how much of it contains abnormal vessels at the start and six months after treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
riboflavin eye drops activated by ultraviolet A light
What this could lead to
If it works, this could offer an eye-drop and light treatment that reduces abnormal blood vessels in the cornea and lowers the risk of transplant rejection.
What could go wrong
The trial is mid-stage and may not show a clear benefit. Light-activated riboflavin can irritate the eye or damage the cornea, and results may not apply to all types of corneal blood vessel growth.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 138 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2021

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years of age or older * With active inflammation or infection causing vascularization and possibly melting of the cornea, or vessels extending into the cornea causing lipid deposition, or vascularization that could significantly increase the risk of rejection of a current or planned corneal transplant, or vessels that continue to extend into the cornea despite topical treatment with corticosteroids. * Signed written informed consent. Exclusion Criteria: * Known sensitivity to treatment medications * Current condition that in the investigator's opinion could compromise safety or data integrity. * Pregnancy (including plan to become pregnant) or lactation during the course of the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Corneal neovascularization are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

corneal neovascularization

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Corneal neovascularization

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Price Vision Group

    RECRUITING

    Indianapolis, Indiana, 46260, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.